So What price should IMC Be ? and why ?, page-10

Are you aware that Tobira was trading at a mere $89 million market cap before Allergan snapped up their NASH drug for $1.7 billion? Arun Sanyal was the principal investigator for Tobira's NASH trial. He thought the drug had promise even though the market trashed the stock on their Phase 2 results. Sanyal is running both our NASH and ASH trials, has an NIH grant paying for the entire Phase 2 ASH trial, was highly impressed with Immuron's Phase 2 March 2018 NASH results, and wrote an affidavit in support of Immuron's 2nd U.S. IMM-124E NASH patent, which was recently granted.